• Investor Relations
• Myriad at a Glance
• Press Releases
• Events & Presentations
• Corporate Governance
• Management Team
• Board of Directors
• Financial Reporting
  • Latest Earnings Release
  • SEC Filings
  • Annual Reports
  • Quarterly Results
  • Key Ratios
• Stock Information
  • Historic Stock Lookup
  • Investment Calculator
  • Dividend History
  • Analyst Coverage
  • Request Information
• Frequently Asked Questions
• Contact

Committee Composition

	Audit	Nominating and Governance	Compensation	Strategic
John T. Henderson, M.D.
Chairman of the Board John T. Henderson, M.D. was elected as Chairman of the Board in April 2005. He previously served as a Director of the Company effective May 2004. Dr. Henderson was with Pfizer for over 25 years, most recently as a Vice President in the Pfizer Pharmaceuticals Group. Dr. Henderson previously held Vice Presidential level positions with Pfizer in Research and Development in Europe and later in Japan. He was also Vice President, Medical for Europe, U.S. and International Pharmaceuticals group. Dr. Henderson earned his bachelor's and medical degree from the University of Edinburgh and is a Fellow of the Royal College of Physicians (Ed.).
Lawrence C. Best
Director Chairman and Founder of OXO Capital LLC Lawrence C. Best, a Director of the Company since September 2009, joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He currently serves on the Board of Directors of Haemonetics Corp. and is a founding director of the President's Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
Heiner Dreismann,, Ph.D.
Director Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
Walter Gilbert, Ph.D.
Director, Vice Chairman of the Board Managing Director, BioVentures Investors Walter Gilbert, Ph.D., Vice Chairman of the Board of Directors, joined the Company as a founding scientist in March 1992. Dr. Gilbert won the Nobel Prize in Chemistry in 1980 for his contributions to the development of DNA sequencing technology. He was a founder of Biogen, Inc. and its Chairman of the Board and Chief Executive Officer from 1981 to 1985, as well as the Carl M. Loeb University Professor at Harvard University. He is presently a Managing Director of BioVentures Investors. Holdings: 0 shares     View Transactions Date Type Shares Traded Price Range Aug 21, 2012 Sell 17,198 26.10 Aug 21, 2012 Option Execute 17,198 16.46 Aug 20, 2012 Sell 42,802 25.94 Aug 20, 2012 Option Execute 42,802 7.60 - 16.46 Sep 5, 2008 Sell 10,000 63.31 Sep 5, 2008 Option Execute 10,000 21.49 - 29.98 Nov 5, 2007 Sell 29,962 52.61 - 53.15 Nov 5, 2007 Option Execute 29,962 17.86 - 21.49 Nov 5, 2007 Sell 5,038 52.76 - 53.05 Nov 5, 2007 Option Execute 5,038 17.86 May 9, 2007 Sell 30,000 38.05 May 9, 2007 Option Execute 30,000 10.19 - 11.22 Nov 10, 2006 Sell 9,498 26.92 Nov 10, 2006 Sell 16,799 26.94 Nov 9, 2006 Sell 3,472 27.14 Nov 9, 2006 Sell 6,171 27.14
Dennis Langer, M.D, J.D.
Director Managing Partner, Phoenix IP Ventures Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. Holdings: 0 shares     View Transactions Date Type Shares Traded Price Range Nov 30, 2012 Sell 45,000 29.89 - 29.92 Nov 30, 2012 Option Execute 45,000 16.46 - 21.66 Nov 29, 2012 Sell 25,000 29.82 - 29.82 Nov 29, 2012 Option Execute 25,000 10.60 - 16.46 Feb 5, 2009 Sell 15,000 82.72 Feb 5, 2009 Option Execute 15,000 21.49 - 29.98 Sep 5, 2008 Sell 4,280 63.50 Sep 5, 2008 Option Execute 4,280 21.49 Sep 4, 2008 Sell 5,720 65.73 Sep 4, 2008 Option Execute 5,720 21.49 Dec 20, 2007 Sell 20,000 47.00 - 48.09 Dec 20, 2007 Option Execute 20,000 17.23 - 19.50 Dec 19, 2007 Sell 10,000 47.50 - 47.53 Dec 19, 2007 Option Execute 10,000 17.23
S. Louise Phanstiel
Director S. Louise Phanstiel joined the Company in September 2009. Ms. Phanstiel held several important positions at WellPoint, Inc. from 1996 to 2007, including President, Specialty Products (2003 to 2007), Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman (2000 to 2003), and Senior Vice President, Chief Accounting Officer, Controller, and Chief Financial Officer for all WellPoint, Inc. subsidiaries, including Blue Cross of California (1996 to 2000). Previously, Ms. Phanstiel was a partner at the international services firm of Coopers and Lybrand where she served clients in life and property/casualty insurance, high technology, and higher education. Ms. Phanstiel formerly served on the Board of Directors of Inveresk Research Group, Inc. and Charles River Laboratories, Inc. Ms. Phanstiel received a B.A. degree in Accounting from Golden Gate University and is a Certified Public Accountant.

= Chair of the Board = Chair = Member = Independent Director

Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.